Latest News

benzodiazepine
Benzodiazepines: Fellow Psychiatrists, We Still Have Work to Do

April 23rd 2024

While benzodiazepine prescribing certainly carries risks, those risks have been demonstrably exaggerated in the minds of government officials, critics, and the public at large.

social anxiety
First Participant Enrolled in Phase 3 Trial of Fasedienol for Social Anxiety Disorder

April 1st 2024

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.
The Week in Review: March 4-8

March 9th 2024

What is new in research on cannabis?
Cannabis Research Roundup: March 8, 2024

March 8th 2024

anxiety
FDA Grants Breakthrough Designation to MM-120 for Generalized Anxiety Disorder

March 7th 2024

Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

© 2024 MJH Life Sciences

All rights reserved.